Dr. Schiller on the Importance of Genomic Testing in AML

Video

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, underscores the importance of genomic testing in acute myeloid leukemia.

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, underscores the importance of genomic testing in acute myeloid leukemia (AML).

It's important to remember that AML is not just one disease, says Schiller. He adds that he remembers urging his colleagues to perform cytogenetics and fluorescence in situ hybridization testing in the past. These tests have become standardized but newer approaches have also emerged, such as molecular testing, next-generation sequencing, and testing with probes.

These approaches have yet to become a standard part of routine practice, but the implications of performing these tests are significant, adds Schiller. For example, the results can help guide initial therapy, therapy after relapse, and inform the use of transplant. Schiller’s advice is to develop molecular testing panels at academic institutions and commercial laboratories to more adequately assess patients with AML.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD